Biofoundries: Pioneering Sustainable Biomanufacturing for a Greener Future

Changes in the biotechnology sector

The past decade has seen an unparalleled expansion and innovation within the bioprocessing sector, driven by the growing significance of bioproduct manufacturing — which increasingly permeates everyday life. Bioprocesses serve as the cornerstone of biotechnology, shaping the bioeconomy by offering the potential to address critical global challenges such as climate change, rapid population growth, and declining ecosystem resilience. The promising convergence of digitalization, biologicalisation, and biomanufacturing has given rise to the emergent paradigm of "bio-intelligent value addition," or Bioprocessing 4.0.?

Bioprocessing 4.0 is an end-to-end digitally controlled bioprocess that involves the digital interconnection of all the systems and equipment. However, despite its promising attributes, Bioprocessing 4.0, faces technical, organizational, and economic challenges?that must be overcome to ensure its successful implementation and advancing the Sustainability Development Goals (SDGs). The persistent demand for expedited delivery of bioproducts underscores the importance of fostering a culture of knowledge sharing, digitalization, automation, and the development of flexible, modular, and popular facility infrastructures.

Presently, over 40 countries have developed national frameworks related to the bioscience-driven economy?and/or biological engineering, including prominent nations such as the United States, the United Kingdom, and Australia. The expansion of bioengineering capabilities — across the entire innovation cycle — is regarded as essential for both enhancing scientific prowess and economic progress and tackling key issues. Introducing novel methods for creating and refining biological elements and systems for use in various biotechnology sectors and focusing on swiftly developing biological systems can offer new solutions to tackle global challenges. The establishment of biofoundries is viewed as a catalyst in accelerating these efforts — providing the infrastructure necessary to advance these cutting-edge developments.

The Need for Biofoundries

Recent advancements in automated, real-time control of bioprocess workflows within the biomanufacturing sector have resulted in reducing variability while enhancing the safety, quality, and efficacy of biologically derived therapeutics. These advancements are largely driven by the biopharmaceutical industry's integration of Process Analytical Technology (PAT)?and Quality by Design (QbD) frameworks. Biofoundries have emerged as critical enablers of rapid and efficient progression through the Design-Build-Test-Learn (DBTL) cycle, transforming both research initiatives and industrial-scale biomanufacturing. State-of-the-art, fully automated facilities — also known as Biofoundries — present an unmatched capability to harmonize biological system construction with advanced process technologies and seamless automation. By enabling the development of proof-of-concept prototypes and iterative models ahead of scale-up, biofoundries empower enterprises of all sizes to expedite their concepts and designs. Moreover, they provide a stable platform for optimizing bioprocesses in key industrial organisms — such as yeast, bacteria, and mammalian cells — through targeted genetic modifications aimed at enhancing metabolic pathways, thus improving both yield and productivity.

Components of Biofoundry

The structure of a biofoundry is intricately designed to integrate advanced technologies, automation, and collaborative spaces — all crucial for enhancing biological design, engineering, and production processes. Central to this facility are core laboratories, including wet labs for hands-on biological experimentation — featuring essential equipment such as incubators and biosafety cabinets — and dry labs dedicated to data analysis and computational modeling, equipped with high-performance computing resources. Automation significantly elevates efficiency, with liquid handling systems and robotic platforms streamlining high-throughput screening and repetitive laboratory tasks. Bioprocessing units, including various bioreactors and fermentation units, facilitate the scaling of biological production under controlled conditions. Additionally, specialized analytical labs utilize advanced techniques like chromatography and mass spectrometry for the characterization of bioproducts, while design studios and prototyping spaces promote rapid iteration and refinement of engineered biological systems. Robust data management infrastructures include machine learning and artificial intelligence applications for optimization, alongside collaboration hubs that encourage interdisciplinary teamwork and networking with external partners. Lastly, a strong emphasis on sustainability and safety ensures compliance with regulatory standards through effective waste management systems and necessary training resources, thereby fostering a safe and innovative environment for research and development in biotechnology.?By integrating advanced technologies and promoting interdisciplinary teamwork, foundries are not only capable of accelerating innovation but are also essential in developing sustainable solutions to meet complex challenges.

Structuring a Biofoundry

A biofoundry ought to evolve organically, commencing from a fundamental platform while aspiring towards heightened automation, equipment interoperability, and operational efficiency. By contemplating strategic frameworks — encompassing process planning, simulation, and optimization — early in the development process, potential bottlenecks can be discerned and mitigated effectively.?By structuring a biofoundry per the Design, Build, Test, Learn (DBTL) framework, organisations can profoundly enhance their agility and responsiveness to swiftly transform the domain of biotechnology. The?Design, Build, Test, Learn (DBTL) cycle promotes the rapid refinement of biological constructs and processes, driving ongoing improvement and innovation within the biofoundry. This approach not only accelerates the emergence of groundbreaking biotechnological innovations but also cultivates an enduring culture of continuous improvement and interdisciplinary collaboration.

A biofoundry developed following this cycle consists of several key phases.?

In the?Design Phase, collaborative design studios should be established as dedicated spaces where teams of scientists, engineers, and bioinformaticians can work together to create biological systems. Using computer-aided design (CAD) tools and simulation software, these teams can model important components such as genetic circuits and metabolic pathways. Additionally, standardized protocols should be implemented to ensure that all components are modular and can be easily integrated — enhancing reproducibility and allowing for smooth modifications based on experimental results.

The Build Phase?focuses on establishing automated workflows and bioprocessing units. The biofoundry should also be equipped with bioreactors and fermentation systems that enable rapid scaling of biological products, allowing for experimentation with various growth conditions and nutrient formulations. Automated systems can facilitate the high-throughput construction of biological systems, minimizing human error and speeding up the assembly of genetic constructs and engineered organisms.

In the Test Phase, analytical and characterization labs should be set up, equipped with advanced tools like chromatography and mass spectrometry to rigorously assess the quality, purity, and yield of the developed bioproducts. Real-time monitoring and data acquisition systems must be implemented to collect key performance metrics during testing, including growth rates and product concentrations.?

Finally,?the?Learn Phase?emphasizes the use of bioinformatics tools and machine learning algorithms to analyze the data generated from tests. This analysis allows researchers to identify patterns, optimize processes, and refine design parameters based on experimental outcomes. An iterative feedback loop encourages continuous learning, where insights from testing inform subsequent design phases.

Improving the Design, Build, Test, Learn (DBTL) framework involves enhancing various aspects of the process to increase efficiency, reduce time-to-market, and foster innovation. The integration of sustainability and compliance is crucial in the foundry framework. To promote eco-friendly practices throughout the Design, Build, Test, Learn (DBTL) cycle, it is essential to prioritize renewable resources, minimize waste and conduct lifecycle assessments during the design phase. Additionally, ensuring regulatory compliance from the outset is vital; this includes implementing safety protocols for handling biological materials and adhering to ethical guidelines, both of which are necessary for maintaining public trust and facilitating market access.

Embracing new age biomanufacturing practices with DDE

The advancement of next-generation biomanufacturing possesses the potential to generate biological treatments aimed at addressing a myriad of critical health conditions. Additionally, integrating high-throughput screening, real-time data analytics, and advanced bioinformatics will empower biofoundries to rigorously evaluate therapeutic efficacy, identify pertinent biomarkers, and inform critical treatment decisions.

DDE envisions biofoundries as pivotal entities that will significantly advance precision medicine by harnessing cutting-edge technologies, automation, and interdisciplinary collaboration to engineer customized therapies. With over four decades of experience, five state-of-the-art manufacturing facilities, and a highly skilled and diverse workforce, we deliver a wide array of innovative turnkey solutions for the biopharma industry. These turnkey solutions span multiple product types, including precision medicine, gene editing, CAR-T and other cell therapies, metabolic engineering, and mRNA vaccines, underscoring DDE’s potential to profoundly impact the bioeconomy.

With India set to emerge as one of the top five global biomanufacturing hubs by 2025, as highlighted by Dr Jitendra Singh, Union Minister of Science & Technology, the biotechnology industry is rapidly adapting to this growing sector. To propel this growth, the Department of Biotechnology is committed to fostering high-performance biomanufacturing through an integrated approach that promotes a circular economy and sustainable manufacturing methods based on synthetic biology. DD Enterprises firmly believes that this approach will foster a collaborative environment that improves research efficiency, streamlines regulatory compliance with sustainable practices, and supports the rapid scaling of production to meet patient demand without compromising quality. As a preeminent leader and innovator in this domain, DDE is committed to supporting biopharma companies in translating groundbreaking biotechnologies — from the Lab Scale to the Production Scale.

?